Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients
NCT: NCT04446416 · COMPLETED
Реклама
NCT IDNCT04446416
СтатусCOMPLETED
Дата начала2020-07-21
Завершение2023-08-04
Краткое описание
This is a prospective, single-arm, two stages, open-label, pilot study to investigate the efficacy and safety of FUS add-on bevacizumab (BEV) in rGBM patients. The BEV is the best physician's choice of standard of care for rGBM after prior radiotherapy and temozolomide chemotherapy in the LinKou Chang Gung Memorial Hospital. Eligible patients will be enrolled through the process of informed consent.
Официальный источник
Открыть на ClinicalTrials.gov →Данные получены через API ClinicalTrials.gov. Актуальный статус смотрите в официальной записи.